POLYPEPTIDES SHOWING ACTIVITY OF PULMONARY SURFACE-ACTIVE SUBSTANCE AND PHARMACEUTICAL COMPOSITION

FIELD: chemistry of peptides. SUBSTANCE: invention describes polypeptides of the formula (I): 0 1 2 3 4 5 6 7 8 9 10 11 12 (A)-Gly-Ile-Pro-B-B-Pro-Val-His-Leu-Lys-Arg-Leu- 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 -Leu-Ile-Val-Val-Val-Val-Val-Val-Leu-Ile-Val-Val-Val-Ile-Val- 28 29 30 31 32 33 34...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	KLAUS P.SHEHFER, UVE KRJUGER, VOL'F-RJUDIGER UL'RIKH, EHRNST SHTURM, KLAUS MEL'KHERS, DITRIKH KHEHFNER, RJUDIGER NAVE
Format:	Patent
Sprache:	eng
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROCESSES USING MICROORGANISMS PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	FIELD: chemistry of peptides. SUBSTANCE: invention describes polypeptides of the formula (I): 0 1 2 3 4 5 6 7 8 9 10 11 12 (A)-Gly-Ile-Pro-B-B-Pro-Val-His-Leu-Lys-Arg-Leu- 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 -Leu-Ile-Val-Val-Val-Val-Val-Val-Leu-Ile-Val-Val-Val-Ile-Val- 28 29 30 31 32 33 34 -Gly-Ala-Leu-Leu-C-Gly-Leu where A means H or Phe, B means Phe or Trp and C means Ile, Leu or Ser that show activity of pulmonary surface-active substance. These polypeptides are synthesized with high yield and high purity degree and their effectiveness is comparable with that to natural pulmonary surface-active substances. They can be used for preparing pharmaceutical compositions used for treatment of newborns and adults with dyspnea syndrome. EFFECT: enhanced effectiveness of polypeptides. 9 cl, 4 ex